Surrogate endpoints and competing risk of death in cardiac arrest research

We urgently need new therapies to improve outcomes after cardiac arrest. Initial studies typically target surrogate endpoints, and these studies help to inform subsequent larger trials that are powered to measure more patient-orientated clinical outcomes such as survival. The competing risk of death...

Descripción completa

Detalles Bibliográficos
Autores principales: McCredie, Victoria A., Scales, Damon C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926290/
https://www.ncbi.nlm.nih.gov/pubmed/27353499
http://dx.doi.org/10.1186/s13054-016-1345-y
Descripción
Sumario:We urgently need new therapies to improve outcomes after cardiac arrest. Initial studies typically target surrogate endpoints, and these studies help to inform subsequent larger trials that are powered to measure more patient-orientated clinical outcomes such as survival. The competing risk of death and premature assessment of neurological prognosis pose significant challenges to measuring these surrogate endpoints after cardiac arrest.

Ejemplares similares